Control Bionics Limited (ASX:CBL)

Market Cap	11.53M
Revenue (ttm)	6.14M
Net Income (ttm)	-6.11M
Shares Out	303.46M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117
Average Volume	51,568
Open	0.0380
Previous Close	0.0370
Day's Range	0.0380 - 0.0380
52-Week Range	0.0260 - 0.0840
Beta	0.02
RSI	54.24
Earnings Date	Aug 22, 2025

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CBL

Financial Performance

In 2025, Control Bionics's revenue was 6.14 million, an increase of 14.84% compared to the previous year's 5.35 million. Losses were -6.11 million, 3.30% more than in 2024.